ClinicalTrials.Veeva
Menu

Find clinical trials for Eczema in Montréal, QC

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Atopic Dermatitis
Dermatitis
Pruritus
Food Hypersensitivity
Hidradenitis
Hidradenitis Suppurativa
Hypersensitivity

Eczema trials near Montréal, QC, CAN:

A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis (ADAPTIVE)

The purpose of this study is to evaluate the efficacy and safety of different dose regimens of IMG-007, compared to placebo.

Enrolling
Atopic Dermatitis Eczema
Eczema
Drug: Placebo
Drug: IMG-007

Phase 2

Inmagene

Montreal, Quebec, Canada and 17 other locations

The goal of this clinical trial is to assess the safety, tolerability, and pharmacokinetics of ATTO-3712 in healthy adults and patients with atopic d...

Not yet enrolling
Atopic Eczema/Dermatitis (Non-Specific)
Atopic Eczema
Drug: ATTO-3712
Drug: Placebo

Phase 1

Attovia Therapeutics Inc

Montreal, Quebec, Canada

The goal of this clinical trial is to assess the safety, tolerability, and pharmacokinetics of ATTO-1310 in healthy adults, patients with atopic derm...

Enrolling
Atopic Eczema
Chronic Pruritus
Drug: ATTO-1310 Placebo
Drug: ATTO-1310

Phase 1

Attovia Therapeutics Inc

Montreal, Quebec, Canada and 13 other locations

the treatment of adults with moderate to severe Atopic Dermatitis (Eczema). OpSCF will be compared to a placebo.OpSCF or placebo will be adm...

Active, not recruiting
Atopic Dermatitis
Biological: Placebo
Biological: OpSCF

Phase 2

Opsidio

Montréal, Quebec, Canada and 21 other locations

The purpose of this study is to evaluate the safety and tolerability of XmAb27564 following multiple doses among participants with plaque psoriasis a...

Active, not recruiting
Atopic Dermatitis
Psoriasis
Biological: XmAb27564
Biological: Placebo

Phase 1

Xencor
Xencor

Montréal, Quebec, Canada and 8 other locations

This trial is designed to evaluate multiple compounds in participants with moderate to severe atopic dermatitis (AD).

Enrolling
Atopic Dermatitis
Drug: Placebo
Drug: GHZ339

Phase 2

Novartis
Novartis

Montreal, Quebec, Canada and 47 other locations

The primary objective of the study is to assess the long-term safety of dupilumab in pediatric participants with AD.The secondary objectives of the s...

Active, not recruiting
Atopic Dermatitis
Drug: Dupilumab

Phase 3

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Montreal, Quebec, Canada and 83 other locations

B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...

Active, not recruiting
Dermatitis, Atopic
Drug: Abrocitinib 200 mg
Drug: Abrocitinib 100 mg

Phase 3

Pfizer
Pfizer

Montreal, Quebec, Canada and 541 other locations

The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.

Active, not recruiting
Atopic Dermatitis
Other: Placebo
Drug: Rocatinlimab

Phase 3

Amgen
Amgen

Montreal, Quebec, Canada and 555 other locations

The objective of this study is to assess the efficacy and safety of upadacitinib combined with topical corticosteroids (TCS) for the treatment of ado...

Invitation-only
Atopic Dermatitis
Drug: Placebo
Drug: Upadacitinib

Phase 3

AbbVie
AbbVie

Montreal, Quebec, Canada and 193 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems